This invention relates to combinations of an auristatin or an auristatin-basedantibody-drug-conjugate (ADC) with second active agents including PI3K/mTORinhibitors,MEK inhibitors, taxanes, or other anti-cancer agents, and methods of treatingabnormal cellgrowth by administering these combinations to patients.